Platelet additive solution having a beta-galactosidase inhibitor
US10271541B2 · kind B2 · utility
0Cited by
67References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Feb 17, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61J1/10
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.